11 news items
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
and atezolizumab. The main goals are to measure how well the treatments work and their safety. Additionally, the study will look at progression-free survival (how
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
. The main goals are to measure how well the treatments work and their safety. Additionally, the study will look at progression-free survival (how long
What's Going On With FibroGen Stock Tuesday?
FGEN
REGN
4 Jun 24
Gal9 levels of expression. Phase 1 trials evaluating the safety and efficacy of FG-3165 in patients with select solid tumors are expected to begin
FibroGen Stock Is Surging After The Bell: What's Going On?
FGEN
REGN
3 Jun 24
trials evaluating the safety and efficacy of FG-3165 in patients with select solid tumors is expected to begin enrollment in the second half of 2024
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
FGEN
3 Jun 24
, safety, and potential success of FibroGen product candidates, and statements about FibroGen's plans and objectives and typically are identified by use
igdbs3os qx4v9lar
FGEN
3 Jun 24
The safety
m1ogpog4yfu6j5effxypgiy9n4pgw4zjspwh9
BNTX
CTMX
FGEN
3 Jun 24
with mFOLFIRINOX, or pelareorep with mFOLFIRINOX and atezolizumab. The co-primary endpoints of the study are objective response rate and safety. Secondary
vow egk8rnmvj7ec
BNTX
CTMX
FGEN
3 Jun 24
with mFOLFIRINOX, or pelareorep with mFOLFIRINOX and atezolizumab. The co-primary endpoints of the study are objective response rate and safety
r58e6vqhqvnpjczta1mb bn
FGEN
23 May 24
patientsFG-3246 demonstrated an acceptable safety profile; adverse events
09fckli n2ihxkrbrzmvsf8oi
FGEN
6 May 24
of 7.5 months.PSA reductions of ≥ 50% were observed in 36% of PSA evaluable patients. Safety analysis: The most
iird0on29ap7o
FGEN
2 Apr 24
FG-3246 demonstrated an acceptable safety profile; adverse events consistent
- Prev
- 1
- Next